BioAge Labs mentioned on Friday it’s discontinuing its mid-stage trial learning its experimental drug as a monotherapy and together with Eli Lilly’s tirzepatide for the remedy of weight problems.
The drug developer determined to cease the trial after liver transaminitis, or excessive ranges of sure liver enzymes, had been noticed in sufferers receiving the experimental drug, azelaprag.
Tirzepatide is the lively ingredient in Lilly’s diabetes drug Mounjaro and weight-loss remedy Zepbound.
The mid-stage trial enrolled about 220 people with weight problems aged 55 years and older.
